Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing toxicities in pelvic malignancies.

Jay Friedland1

  • 1University Community Hospital, Center for Cancer Care, Tampa, FL 33613, USA. jfriedland@mail.uch.org

The Journal of Supportive Oncology
|December 21, 2004
PubMed
Summary

Amifostine (Ethyol) can reduce radiation side effects like rectal bleeding and skin issues in pelvic cancer patients. This protection helps maintain quality of life and ensures effective cancer treatment without harming tumor control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience.

Urologic oncologyยท2006
See all related articles

Area of Science:

  • Oncology
  • Radiation Oncology
  • Pharmacology

Background:

  • Pelvic malignancies require radiation therapy, often causing significant toxicities.
  • Minimizing radiation-related side effects is crucial for patient quality of life and treatment adherence.
  • Improved toxicity management can prevent radiotherapy delays, potentially enhancing cure rates.

Purpose of the Study:

  • To evaluate the efficacy of amifostine (Ethyol) in mitigating radiation-induced toxicities in patients with pelvic cancers.
  • To assess the impact of amifostine on rectal bleeding, dermatitis, and mucosal protection.
  • To determine if amifostine affects local or distant tumor control in patients undergoing radiotherapy.

Main Methods:

  • The study involved patients with pelvic malignancies undergoing radiation therapy.
  • Amifostine (Ethyol) was administered to assess its protective effects.
  • Outcomes measured included rectal bleeding, radiation dermatitis, mucosal integrity, and tumor control.

Main Results:

  • Amifostine demonstrated a reduction in rectal bleeding for prostate cancer patients.
  • The drug effectively prevented radiation-related dermatitis.
  • Widespread mucosal protection was observed without compromising tumor control.

Conclusions:

  • Amifostine (Ethyol) is a viable option for reducing radiation-related toxicities in pelvic cancer patients.
  • Its use can improve quality of life and treatment compliance.
  • Amifostine provides significant protective benefits without negatively impacting oncologic outcomes.

Related Experiment Videos